RxDoctor Payments Data

Gregory Jia, MD

Urology · Oklahoma City, OKNPI 1922084128

Payments from drug & device makers

$3,895in general payments, 2019–2025

Across 146 payments — averaging $26.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$652
  • Medtronic$497
  • Sumitomo Pharma America, Inc.$354
  • Teleflex LLC$327
  • Boston Scientific$276
  • Coloplast$270
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$3,77297%
  • Education$1103%
  • Entertainment$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,895 in reported general payments places this provider in the 50th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$163,794
Medicare patients
517
Services billed
1,221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron51$54,727
GemtesaVibegron22$18,239
Tamsulosin Hcl663$10,255
Silodosin63$6,015
Oxybutynin Chloride ErOxybutynin Chloride140$3,230
Testosterone15$1,922
Alfuzosin Hcl ErAlfuzosin Hcl48$1,808
Trimethoprim33$1,415
Finasteride53$719
Ciprofloxacin Hcl112$574
Solifenacin Succinate15$551
Testosterone Cypionate13$422
Mirtazapine12$390
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$366
Levofloxacin46$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$652$54,72751 claims
Sumitomo Pharma America, Inc.Gemtesa$354$18,23922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 145 urology providers in Oklahoma.

Other urology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →